(Q38011962)

27 August 2017

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia (English)

1 reference

27 August 2017

1 reference

R Swords

1

1 reference

27 August 2017

C Freeman

series ordinal

2

1 reference

27 August 2017

F Giles

series ordinal

3

1 reference

27 August 2017

27 April 2012

1 reference

27 August 2017

1 reference

27 August 2017

26

1 reference

27 August 2017

2176-2185

1 reference

27 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.114

27 August 2017

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Genetics of myeloid malignancies: pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Current findings for recurring mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Risk assessment in patients with acute myeloid leukemia and a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Further activation of FLT3 mutants by FLT3 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Critical importance of the cell system when studying tissue factor de-encryption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Monoclonal antibody-based therapeutics for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

FLT3 antibody-based therapeutics for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Anti-human FLT3 monoclonal antibody that inhibits proliferation of monocytic leukemia cell line SHI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Prognostic significance of FLT3 ITD and D835 mutations in AML patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Screens, iron, and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.114

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.114

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference